Literature DB >> 17652182

Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice.

Qingen Ke1, Yong-Fu Xiao, J Alyce Bradbury, Joan P Graves, Laura M Degraff, John M Seubert, Darryl C Zeldin.   

Abstract

CYP2J2 is abundant in cardiac tissue and active in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs). To determine the effects of CYP2J2 and its eicosanoid products in the heart, we characterized the electrophysiology of single cardiomyocytes isolated from adult transgenic (Tr) mice with cardiac-specific overexpression of CYP2J2. CYP2J2 Tr cardiomyocytes had a shortened action potential. At 90% repolarization, the action potential duration (APD) was 30.6 +/- 3.0 ms (n = 22) in wild-type (Wt) cells and 20.2 +/- 2.3 ms (n = 19) in CYP2J2 Tr cells (p < 0.005). This shortening was probably due to enhanced maximal peak transient outward K(+) currents (I(to,peak)), which were 38.6 +/- 2.8 and 54.4 +/- 4.9 pA/pF in Wt and CYP2J2 Tr cells, respectively (p < 0.05). In contrast, the late portion of the transient outward K(+) current (I(to,280ms)), the slowly inactivating outward K(+) current (I(K,slow)), and the voltage-gated Na(+) current (I(Na)) were not significantly altered in CYP2J2 Tr cells. N-Methylsulphonyl-6-(2-proparglyloxy-phenyl)hexanamide (MS-PPOH), a specific inhibitor of EET biosynthesis, significantly reduced I(to,peak) and increased APD in CYP2J2 Tr cardiomyocytes but not in Wt cells. Intracellular dialysis with a monoclonal antibody against CYP2J2 also significantly reduced I(to,peak) and increased APD in CYP2J2 Tr cardiomyocytes. Addition of 11,12-EET or 8-bromo-cAMP significantly reversed the MS-PPOH- or monoclonal antibody-induced changes in I(to,peak) and APD in CYP2J2 Tr cells. Together, our data demonstrate that shortening of the action potential in CYP2J2 Tr cardiomyocytes is associated with enhanced I(to,peak) via an EET-dependent, cAMP-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652182      PMCID: PMC2243182          DOI: 10.1124/mol.107.035881

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

Review 1.  Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.

Authors:  John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2005-09

2.  Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium.

Authors:  J Vriens; G Owsianik; B Fisslthaler; M Suzuki; A Janssens; T Voets; C Morisseau; B D Hammock; I Fleming; R Busse; B Nilius
Journal:  Circ Res       Date:  2005-09-22       Impact factor: 17.367

3.  Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes.

Authors:  H C Lee; T Lu; N L Weintraub; M VanRollins; A A Spector; E F Shibata
Journal:  J Physiol       Date:  1999-08-15       Impact factor: 5.182

4.  Elimination of the transient outward current and action potential prolongation in mouse atrial myocytes expressing a dominant negative Kv4 alpha subunit.

Authors:  H Xu; H Li; J M Nerbonne
Journal:  J Physiol       Date:  1999-08-15       Impact factor: 5.182

5.  Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells.

Authors:  Y F Xiao; L Huang; J P Morgan
Journal:  J Physiol       Date:  1998-05-01       Impact factor: 5.182

6.  Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel.

Authors:  Eric R Gross; Kasem Nithipatikom; Anna K Hsu; Jason N Peart; John R Falck; William B Campbell; Garrett J Gross
Journal:  J Mol Cell Cardiol       Date:  2004-12       Impact factor: 5.000

7.  Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes.

Authors:  M P Moffat; C A Ward; J R Bend; T Mock; P Farhangkhoee; M Karmazyn
Journal:  Am J Physiol       Date:  1993-04

8.  Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2.

Authors:  Yong-Fu Xiao; Qingen Ke; John M Seubert; J Alyce Bradbury; Joan Graves; Laura M Degraff; John R Falck; Kris Krausz; Harry V Gelboin; James P Morgan; Darryl C Zeldin
Journal:  Mol Pharmacol       Date:  2004-09-10       Impact factor: 4.436

9.  Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury.

Authors:  Kasem Nithipatikom; Jeannine M Moore; Marilyn A Isbell; John R Falck; Garrett J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-02-10       Impact factor: 4.733

10.  Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway.

Authors:  Mairéad A Carroll; Anabel B Doumad; Jing Li; Monica K Cheng; J R Falck; John C McGiff
Journal:  Am J Physiol Renal Physiol       Date:  2006-02-14
View more
  11 in total

1.  Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog.

Authors:  Garrett J Gross; Kathryn M Gauthier; Jeannine Moore; William B Campbell; John R Falck; Kasem Nithipatikom
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-15       Impact factor: 4.733

2.  Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice.

Authors:  Rui Li; Xizhen Xu; Chen Chen; Xuefeng Yu; Matthew L Edin; Laura Miller Degraff; Craig R Lee; Darryl C Zeldin; Dao Wen Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-10-02       Impact factor: 3.072

3.  Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Authors:  Garrett J Gross; Kathryn M Gauthier; Jeannine Moore; John R Falck; Bruce D Hammock; William B Campbell; Kasem Nithipatikom
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-25       Impact factor: 4.733

4.  Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway.

Authors:  Yong-Fu Xiao; Alena Nikolskaya; Deborah A Jaye; Daniel C Sigg
Journal:  Cardiovasc Diabetol       Date:  2011-01-20       Impact factor: 9.951

5.  CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy.

Authors:  Christina Westphal; Bastian Spallek; Anne Konkel; Lajos Marko; Fatimunnisa Qadri; Laura M DeGraff; Carola Schubert; J Alyce Bradbury; Vera Regitz-Zagrosek; John R Falck; Darryl C Zeldin; Dominik N Müller; Wolf-Hagen Schunck; Robert Fischer
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

6.  Adenosine A2a Receptor Regulates Autophagy Flux and Apoptosis to Alleviate Ischemia-Reperfusion Injury via the cAMP/PKA Signaling Pathway.

Authors:  Yun Xia; Feng He; Mohamed Bassirou Moukeila Yacouba; Huimin Zhou; Jingfan Li; Ying Xiong; Jingjing Zhang; Hui Li; Yanlin Wang; Jianjuan Ke
Journal:  Front Cardiovasc Med       Date:  2022-04-29

7.  Transcription factors MYOCD, SRF, Mesp1 and SMARCD3 enhance the cardio-inducing effect of GATA4, TBX5, and MEF2C during direct cellular reprogramming.

Authors:  Nicolas Christoforou; Malathi Chellappan; Andrew F Adler; Robert D Kirkton; Tianyi Wu; Russell C Addis; Nenad Bursac; Kam W Leong
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

8.  Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2.

Authors:  Pierre Lafite; François André; Joan P Graves; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

Review 9.  Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes.

Authors:  Theresa Aliwarga; Eric A Evangelista; Nona Sotoodehnia; Rozenn N Lemaitre; Rheem A Totah
Journal:  Int J Mol Sci       Date:  2018-06-29       Impact factor: 5.923

10.  CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice.

Authors:  Xuguang Li; Feng Zhu; Weidong Meng; Feng Zhang; Jiang Hong; Guobing Zhang; Fang Wang
Journal:  J Cell Mol Med       Date:  2019-11-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.